Intoxikon, USAEmail: email@example.com
Research Interest: Dr. Ge’s research focuses on protection of ischemic myocardium against ischemia and reperfusion injury. This includes the application of volatile anesthetics, adenosine receptor agonists, and ischemic preconditioning, the phenomenon in which myocardium exposed to brief, repeated periods of sublethal ischemia becomes resistant to the deleterious effects of ischemia or reperfusion. Recent evidence from this lab indicates thatgenetic modulation of GTP cyclohydrolase 1 to increase cardiac tetrahydrobiopterin and nitric oxide production can protect myocardium from ischemia and reperfusion injuryand preserve the ability of ischemic preconditioning to elicit cardioprotection that is impaired by hyperglycemia. Further investigations are being actively conducted, including the mechanisms underlying myocardial protection by overexpression of GTP cyclohydrolase 1 gene in the presence of hyperglycemia and diabetes and the potential of GTP cyclohydrolase 1 overexpression in reducing maladaptive myocardial remodeling followinginfarction in diabetic and nondiabetic myocardium.
In 1995 Dr. Blum retired from the University of Texas Health Science Center giving up tenure to enter the world of business and biotechnology. In the second year, acting as manager of 1899 Limited Liability Corporation, his first weight management product grossed in excess of 60 million retail. His company Cyberpharm has launched a weight loss system with Rexall/Showcase which was launched early 1999. Dr. Blum continues to publish research articles, writes books (twelve), lectures, and is actively applying for numerous patents in the field of molecular genetics & nutrition. Dr. Blum is very active as Scientific Director of the Path Medical Foundation and former co-founder and Vice President of the American College of Addictionology and Compulsive Disorders. Dr. Blum is co-founder and Chairman& CSO of Impact Genomics and Managing Partner of IGENE, LLC. He is currently Chief Scientific Officer of G&G HealthCare Services, Inc. and Genomics HealthCare, LLC. His concept of Reward Deficiency Syndrome is being embraced by world leaders in science and is part of the DSM –V, and the DRD2 gene discovery has been confirmed in over 4,000 publications from laboratories all over the world. He serves as Editor –in-Chief Omics Journal of Genetic Syndromes & Gene Therapy, Journal of Addiction Research & Therapy and Genetic Diseases & Genetic Reports, and is currently serving on twelve other prestigious journal’s editorial Boards. He has recently accepted the position of Chief Scientific Officer of Journal operations, Aperito, Publishing House. Currently he has been named Volunteer Full Professor of the Department of Psychiatry & McKnight Brain Institute University of Florida College of Medicine, Gainesville, Florida and Adjunct Research Professor, Human Integrated Services Unit University of Vermont Center for Clinical & Translational Science, College of Medicine, Burlington, VT. He currently serves as neuroscience advisor for Dominion Diagnostics, LLC North Kingstown Rhode Island; G &G Holistic Addiction Treatment center, North Miami Beach Florida and Malibu Beach Recovery Center, Malibu Beach, California. Many consider him as the “Father of Psychiatric Genetics” and “Father of Neuro- Nutrient Therapy”. Dr. Blum received the Life Time Achievement Award from the National Institute of Holistic Addiction Studies 2011, the 2012 Scientific Achievement Award in a Gala Celebrity Event, Miami Beach Florida and Best Abstract Award from the American Society of Anesthesiology and Pain. He and Mark Gold recently signed with Springer as Series editor for Neuroscience of Addiction: A Reference Work which includes four volumes to be published in 2015. Dr. Blum has been notified by Research Gate that is Reputation Score is higher than 97.5% of all scientists in the network to date scoring 40.5. He has also accepted a distinguished appointment of Scientific Advisory Board of NVP's newly formed and funded portfolio company.
Research Interest: Alcohol-dependence, insomnia, cognitive-behavior therapy for insomnia, Internet intervention and health effects of underground spaces.
Research Interest: Neuropharmacology, genetics, neurologic, psychiatric and neurodegenerative disorders, cell culture, animal models, patients
Research Interest: Benzodiazepine dependence, alcohol dependence, withdrawal symptoms, psychopharmacology,valproate, lithium, lamotrigine, bipolar disorder, adherence, brain imaging, suicide
Research Interest: His recent focus is on gaining a better understanding the role of muscarinic receptors for cognitive dysfunctions in schizophrenia.
Research Interest: My research helps to identify the role of NAc circuitry and neural mechanisms underlying drug addiction.
Research Interest: Elucidation of the molecular mechanisms controlling pathological neuronal activity in addiction and depression, and its application to the relevant disease therapeutics
Research Interest: My research interest is associated with neurochemical factors and their correlation with environmental stimuli in the stress response, and how these factors are associated with vulnerability to drug abuse.
Research Interest: violent behavior and mental disorder; sexual crimes and mental disorder; personality disorders and violent behaviour
Research Interest: Dr. Dannon is internationally recognized for his research and publications in the psychiatric treatment of depression, panic disorder, and behavioral addictions, including kleptomania, Internet addiction, and pathological gambling.
Research Interest: Psychology & Addiction; Neuroscience & Addiction; Psyhopharmacology & Addiction; Addictive Behaviors; Addiction & Criminology
Research Interest: Opiate addiction, gambling addiction, alcohol misuse, legal highs, addiction in young people, gambling in developing countries, etc
Research Interest: Psychiatry, Depression, Neuroimaging, Mood Disorders, Anxiety Disorders, Psychosis, Schizophrenia, Anxiety
Research Interest: Calcohol dependence, stem cell therapy, Internet overuse, addiction psychiatry.
Published On: October 24, 2017 | Pages: 032 - 041Abstract View Full Article View DOI: 10.17352/2455-3484.000024
Published On: August 31, 2017 | Pages: 030 - 031Abstract View Full Article View DOI: 10.17352/2455-3484.000023
Published On: July 14, 2017 | Pages: 024 - 029Abstract View Full Article View DOI: 10.17352/2455-3484.000022
Published On: May 12, 2017 | Pages: 016 - 023Abstract View Full Article View DOI: 10.17352/2455-3484.000021
Published On: April 10, 2017 | Pages: 011 - 015Abstract View Full Article View DOI: 10.17352/2455-3484.000020
Published On: March 14, 2017 | Pages: 007 - 010Abstract View Full Article View DOI: 10.17352/2455-3484.000019
Published On: February 22, 2017 | Pages: 001 - 006Abstract View Full Article View DOI: 10.17352/2455-3484.000018
Published On: December 26, 2016 | Pages: 023 - 027Abstract View Full Article View DOI: 10.17352/2455-3484.000017
Published On: December 17, 2016 | Pages: 019 - 022Abstract View Full Article View DOI: 10.17352/2455-3484.000016
Published On: December 02, 2016 | Pages: 013 - 018Abstract View Full Article View DOI: 10.17352/2455-3484.000015